About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a publicly listed company based in Dublin (Ireland) founded in 2003 by Bruce C Cozadd. Novel biopharmaceutical medicines are developed for unmet medical needs. Jazz Pharmaceuticals has raised $265 million across 3 funding rounds from investors including KKR, Thoma Bravo and Longitude Capital. The company has 2,800 employees. Jazz Pharmaceuticals has completed 5 acquisitions, including Cavion, Chimerix and EUSA Pharma. Its chief executive, as recorded, is Bruce C Cozadd. Its website jazzpharma.com draws about 86 thousand monthly visits. Jazz Pharmaceuticals offers products and services including Epidiolex, Xywav, and Defitelio. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Jazz Pharmaceuticals plc.
Company details
Jazz Pharmaceuticals was founded in 2003 and is headquartered in Dublin, Ireland. Biopharmaceutical products are developed and commercialized by the company to address unmet medical needs across various therapeutic areas. Clinical trial programs are conducted to support these medicines, alongside patient support resources. Research is prioritized based on patient requirements, with advancements made in treating specific conditions. Corporate giving and sustainability initiatives are also pursued.
- Headquarters Dublin, Ireland
- Employees 2,800
- Founders Bruce C Cozadd
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website jazzpharma.com
- Social LinkedIn X Facebook YouTube
- Legal Name Jazz Pharmaceuticals Plc
- Annual Revenue$4.27 B (USD)4.88as on Dec 31, 2025
- Net Profit-$356.15 M (USD)-163.58as on Dec 31, 2025
- EBITDA$1.45 B (USD)4.38as on Dec 31, 2025
- Total Equity Funding$265M (USD)
in 3 rounds
- Latest Funding Round$7M (USD), Post-IPO
Jul 2009
- InvestorsKKR
& 11 more
- Employee Count2,800
- Investments & AcquisitionsCavion
& 4 more
Products & Services of Jazz Pharmaceuticals
Jazz Pharmaceuticals offers a comprehensive portfolio of products and services, including Epidiolex, Xywav, and Defitelio.
Cannabidiol-based treatment for epilepsy and seizures.
Oral solution for narcolepsy and related disorders.
Treatment for severe hepatic veno-occlusive disease.
Apps and channels of Jazz Pharmaceuticals
Jazz Pharmaceuticals publishes 1 mobile app with over 1K+ downloads; its YouTube channel Jazz Pharmaceuticals has 93 subscribers and 24 videos.
Videos from Jazz Pharmaceuticals
The most watched videos on Jazz Pharmaceuticals's YouTube channel, Jazz Pharmaceuticals (93 subscribers). Click a video to play it here.
More on Jazz Pharmaceuticals.
Funding Insights of Jazz Pharmaceuticals
Jazz Pharmaceuticals has successfully raised a total of $265M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7 million completed in July 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $265M
- Total Rounds 3
- Last Round Post-IPO — $7M
- First Round $15M
(Apr 2003)
- Investors Count 12
All 3 funding rounds of Jazz Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2009 | $7M | Post-IPO | – | – | |
| Mar 2004 | $250M | Series B | – | KKR | |
| Apr 2003 | $15M | Series A | – | Prospect Venture Partners, Versant Ventures | – |
12 investors in total: 12 institutional.
Investors in Jazz Pharmaceuticals
Jazz Pharmaceuticals has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, Thoma Bravo and Longitude Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
US healthcare investments are managed by EGS Healthcare Capital Partners. | egshealthcare.com | Norwalk, United States | ||
Private equity investments, business building, and long-term partnerships in finance and investment sectors. | goldengatecap.com | |||
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Buyouts are targeted by BPOC, a private equity firm. | bpoc.com | Chicago, United States | ||
Mid market focused private equity firm | oakhill.com | New York, United States | ||
Mid-market companies are targeted for private equity investments. | waudcapital.com | Chicago, United States |
Investor details for Jazz Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Jazz Pharmaceuticals
792 people are tracked at Jazz Pharmaceuticals (423 in leadership, 12 in board & advisors, 357 in team); the tracked headcount is 2,800.
| Name | Role | Group |
|---|---|---|
Bruce C Cozadd | Co-Founder & CEO | Leadership |
Matt Lasmanis | Chief Digital Officer (cdo) | Leadership |
Patricia Carr | Senior Vice President, Chief Accounting Officer | Leadership |
Ngozi Nina K. | Global Strategic Market Insights, Director | Leadership |
Kenneth Low | Director, Omnichannel Strategic Partner | Leadership |
Ramya Nair | Director Global Strategic Market Insights | Leadership |
Anthony O. | Director, Global Strategic Market Insights | Leadership |
Heidi Manna | EVP & Chief People Officer | Leadership |
Robert Iannone | EVP, R&D & Chief Medical Offer | Leadership |
Yajun Liu | Director Of Clinical Pharmacology | Leadership |
Joshua Allen | Chief Scientific Officer, Oncology | Leadership |
Matt Kosior | Director, Corporate And Securities Counsel | Leadership |
Tej Grewal | Director, Talent Solutions | Leadership |
Sonia Hardaway | Head Of Organizational And Talent Solutions | Leadership |
Jessica Sacks | Associate Medical Director, Sleep | Leadership |
Joanne | Executive Director And Clinical Pharmacology Oncology TA Head | Leadership |
Kedar Vaidya | Associate Director - Pharmacology, Early Development (oncology) | Leadership |
Ju Shi | Associate Director, Pharmacology | Leadership |
Stefanie Bronson | Director, Medical Communications | Leadership |
Purvi Dev | Senior Director, Commercial Forecasting And Analytics | Leadership |
772 more people are available in the full profile.
Complete people profiles for Jazz Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Jazz Pharmaceuticals
Jazz Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol JAZZ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jun 2007
- Listed onNASDAQ: JAZZ
- Listed entityJazz Pharmaceuticals plc
- Exchange sectorHealth technology
- ISINIE00B4Q5ZN47
- Share price$210.39 (-2.93% on the day) · 2026-10-13
- Market capitalisation$13.66B
- Price to earnings14.5
- EPS (diluted, trailing year)$14.50
- Volume (last session)812,641
Financials of Jazz Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $4.27B | -$356.1M | $1.45B |
| 2024 | $4.07B | $560.1M | $1.39B |
| 2023 | $3.83B | $414.8M | $1.30B |
| 2022 | $3.66B | -$224.1M | $1.35B |
| 2021 | $3.09B | -$329.7M | $951.8M |
Detailed financial statements for Jazz Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jazz Pharmaceuticals
Jazz Pharmaceuticals has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Cavion, Chimerix and EUSA Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antiviral oral therapeutics are developed for infectious diseases and cancers. | chimerix.com | Durham, United Kingdom | 2002 | Mar 2025 | $935M | |
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy | gwpharm.com | Cambridge, United Kingdom | 1998 | Feb 2021 | $7.2B | |
Targeted therapies for neuropathic pain and brain cancer are developed. | cavionpharma.com | Charlottesville, United States | 2005 | Aug 2019 | $313M | |
Fish processing machinery and spare parts are manufactured. | gentium.com | Villa Guardia, Italy | 1993 | Dec 2013 | $1B | |
Developer and commercializer of pharmaceutical medicines | eusapharma.com | Hemel Hempstead, United Kingdom | 2006 | Apr 2012 | $650M |
Complete acquisition details for Jazz Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Jazz Pharmaceuticals
9 dated milestones of Jazz Pharmaceuticals across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Jazz Pharmaceuticals is founded.
- Funding First funding round of $15.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $7.0M.
- Acquisition Acquires EUSA Pharma.
- Acquisition Acquires Gentium.
- Acquisition Acquires Cavion.
- Acquisition Acquires GW Pharma.
- Acquisition Acquires Chimerix.
Web traffic of Jazz Pharmaceuticals
The website of Jazz Pharmaceuticals (jazzpharma.com) receives about 86.1K visits a month and ranks #530,349 among all websites worldwide, #547 in Biotechnology and Pharmaceuticals.
- Monthly visits86.1K
▲ 23.7% vs previous month
- Unique visitors36K
per month
- Global rank#530,349
among all websites
- Category rank#547
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit1.8
- Average visit44 sec
- DevicesDesktop 51% · Mobile 49%
Websites whose visitors overlap most with Jazz Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| endo.com | 100% | 10K | #2,323,439 | View details | |
| covance.com | 83% | 20.2K | #688,229 | View details | |
| allos.com | 83% | View details | |||
| acceleronpharma.com | 83% | View details | |||
| unither.com | 83% | 32.2K | #968,866 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 27 similar websites and full traffic analytics for Jazz Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jazz Pharmaceuticals
Complete news archive for Jazz Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jazz Pharmaceuticals
Jazz Pharmaceuticals was founded in 2003.
Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
Bruce C Cozadd is the CEO of Jazz Pharmaceuticals, as recorded in our data. They have also founded this company.
Jazz Pharmaceuticals is a funded company, having raised a total of $265M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15M, raised on Apr 2003.
Jazz Pharmaceuticals has 2,800 employees.
Annual revenue of Jazz Pharmaceuticals is $4.27B as on Dec 31, 2025.
Jazz Pharmaceuticals was founded in 2003 and is headquartered in Dublin, Ireland. Biopharmaceutical products are developed and commercialized by the company to address unmet medical needs across various therapeutic areas. Clinical trial programs are conducted to support these medicines, alongside patient support resources. Research is prioritized based on patient requirements, with advancements made in treating specific conditions. Corporate giving and sustainability initiatives are also pursued.
Jazz Pharmaceuticals offers Epidiolex, Xywav, and Defitelio.
Yes, Jazz Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol JAZZ.
Jazz Pharmaceuticals has made 5 acquisitions, including Cavion, Chimerix, and EUSA Pharma.
Jazz Pharmaceuticals has 12 investors. Key investors include KKR, Thoma Bravo, Longitude Capital, Adams Street Partners, and Versant Ventures.
Jazz Pharmaceuticals operates through Jazz Pharmaceuticals Plc.